PFG Investments LLC Has $1.35 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

PFG Investments LLC trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 67.6% in the 1st quarter, Holdings Channel reports. The institutional investor owned 11,999 shares of the biopharmaceutical company’s stock after selling 25,026 shares during the period. PFG Investments LLC’s holdings in Gilead Sciences were worth $1,345,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Annis Gardner Whiting Capital Advisors LLC lifted its holdings in Gilead Sciences by 158.8% in the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 216 shares during the last quarter. Whipplewood Advisors LLC acquired a new stake in Gilead Sciences in the 4th quarter worth approximately $35,000. Investment Research & Advisory Group Inc. lifted its holdings in Gilead Sciences by 33.3% in the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 100 shares during the last quarter. Synergy Investment Management LLC acquired a new stake in Gilead Sciences in the 4th quarter worth approximately $40,000. Finally, Lee Danner & Bass Inc. acquired a new stake in Gilead Sciences in the 4th quarter worth approximately $41,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

GILD opened at $108.50 on Friday. The stock has a market cap of $134.97 billion, a PE ratio of 22.84, a P/E/G ratio of 0.70 and a beta of 0.29. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16. Gilead Sciences, Inc. has a 1 year low of $66.01 and a 1 year high of $119.96. The stock’s 50 day simple moving average is $106.16 and its 200-day simple moving average is $102.81.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The firm had revenue of $6.67 billion for the quarter, compared to analysts’ expectations of $6.77 billion. During the same period in the prior year, the business posted ($1.32) earnings per share. The business’s revenue was down .3% compared to the same quarter last year. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.91%. The ex-dividend date is Friday, June 13th. Gilead Sciences’s dividend payout ratio (DPR) is 66.53%.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on GILD shares. JPMorgan Chase & Co. boosted their target price on Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, March 27th. Cantor Fitzgerald began coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $125.00 price target on the stock. Oppenheimer dropped their price target on Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, April 25th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Finally, Wells Fargo & Company lifted their price target on Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Nine equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $110.55.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $99.82, for a total value of $249,550.00. Following the sale, the chief financial officer now directly owns 165,674 shares in the company, valued at $16,537,578.68. This represents a 1.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the completion of the sale, the insider now owns 121,152 shares in the company, valued at $13,026,263.04. This trade represents a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 48,500 shares of company stock worth $5,236,245 over the last three months. Company insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.